Multimodal speech biomarkers for remote monitoring of ALS disease progression
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that severely impacts affected persons’ speech and motor functions, yet early detection and tracking of disease progression remain challenging. The current gold standard for monitoring ALS progression, the ALS functional...
Gespeichert in:
Veröffentlicht in: | Computers in biology and medicine 2024-09, Vol.180, p.108949, Article 108949 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 108949 |
container_title | Computers in biology and medicine |
container_volume | 180 |
creator | Neumann, Michael Kothare, Hardik Ramanarayanan, Vikram |
description | Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that severely impacts affected persons’ speech and motor functions, yet early detection and tracking of disease progression remain challenging. The current gold standard for monitoring ALS progression, the ALS functional rating scale - revised (ALSFRS-R), is based on subjective ratings of symptom severity, and may not capture subtle but clinically meaningful changes due to a lack of granularity. Multimodal speech measures which can be automatically collected from patients in a remote fashion allow us to bridge this gap because they are continuous-valued and therefore, potentially more granular at capturing disease progression. Here we investigate the responsiveness and sensitivity of multimodal speech measures in persons with ALS (pALS) collected via a remote patient monitoring platform in an effort to quantify how long it takes to detect a clinically-meaningful change associated with disease progression. We recorded audio and video from 278 participants and automatically extracted multimodal speech biomarkers (acoustic, orofacial, linguistic) from the data. We find that the timing alignment of pALS speech relative to a canonical elicitation of the same prompt and the number of words used to describe a picture are the most responsive measures at detecting such change in both pALS with bulbar (n = 36) and non-bulbar onset (n = 107). Interestingly, the responsiveness of these measures is stable even at small sample sizes. We further found that certain speech measures are sensitive enough to track bulbar decline even when there is no patient-reported clinical change, i.e. the ALSFRS-R speech score remains unchanged at 3 out of a total possible score of 4. The findings of this study have the potential to facilitate improved, accelerated and cost-effective clinical trials and care.
•Multimodal speech biomarkers can be reliably extracted from remote recordings.•Nine features showed significant longitudinal changes in people with ALS.•Canonical timing alignment quickly detected clinically relevant changes.•Findings were stable with small samples; uncertainty increases with fewer data.•Speech features detected changes even when ALSFRS-R showed no change. |
doi_str_mv | 10.1016/j.compbiomed.2024.108949 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3091287172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010482524010345</els_id><sourcerecordid>3096657183</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1926-371bef379c93385d3ed54bb16eb6a927483e684106ca29836b3ed3859b5129233</originalsourceid><addsrcrecordid>eNqFkF1LwzAUhoMoOqd_QQLeeNOZjzZNLufwCza8UK9Dm57OzLaZSSv4703ZRPDGq0DynPc9eRDClMwooeJ6MzOu3ZbWtVDNGGFpvJYqVQdoQmWuEpLx9BBNCKEkSSXLTtBpCBtCSEo4OUYnXFEmcikmaLUamt62rioaHLYA5g2PsYV_Bx9w7Tz20LoecOs62ztvuzV2NZ4vn3FlAxQB8Na7tYcQrOvO0FFdNAHO9-cUvd7dviwekuXT_eNivkwMVUwkPKcl1DxXRnEus4pDlaVlSQWUolAsTyUHIVNKhCmYklyUkYigKjPKFON8iq52ubH7Y4DQ69YGA01TdOCGoDmJH5Q5zVlEL_-gGzf4Lm43UkJkOZVjoNxRxrsQPNR662208KUp0aNyvdG_yvWoXO-Ux9GLfcFQjm8_gz-OI3CzAyAa-bTgdTAWOgOV9WB6XTn7f8s3k06V4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3096657183</pqid></control><display><type>article</type><title>Multimodal speech biomarkers for remote monitoring of ALS disease progression</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Neumann, Michael ; Kothare, Hardik ; Ramanarayanan, Vikram</creator><creatorcontrib>Neumann, Michael ; Kothare, Hardik ; Ramanarayanan, Vikram</creatorcontrib><description>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that severely impacts affected persons’ speech and motor functions, yet early detection and tracking of disease progression remain challenging. The current gold standard for monitoring ALS progression, the ALS functional rating scale - revised (ALSFRS-R), is based on subjective ratings of symptom severity, and may not capture subtle but clinically meaningful changes due to a lack of granularity. Multimodal speech measures which can be automatically collected from patients in a remote fashion allow us to bridge this gap because they are continuous-valued and therefore, potentially more granular at capturing disease progression. Here we investigate the responsiveness and sensitivity of multimodal speech measures in persons with ALS (pALS) collected via a remote patient monitoring platform in an effort to quantify how long it takes to detect a clinically-meaningful change associated with disease progression. We recorded audio and video from 278 participants and automatically extracted multimodal speech biomarkers (acoustic, orofacial, linguistic) from the data. We find that the timing alignment of pALS speech relative to a canonical elicitation of the same prompt and the number of words used to describe a picture are the most responsive measures at detecting such change in both pALS with bulbar (n = 36) and non-bulbar onset (n = 107). Interestingly, the responsiveness of these measures is stable even at small sample sizes. We further found that certain speech measures are sensitive enough to track bulbar decline even when there is no patient-reported clinical change, i.e. the ALSFRS-R speech score remains unchanged at 3 out of a total possible score of 4. The findings of this study have the potential to facilitate improved, accelerated and cost-effective clinical trials and care.
•Multimodal speech biomarkers can be reliably extracted from remote recordings.•Nine features showed significant longitudinal changes in people with ALS.•Canonical timing alignment quickly detected clinically relevant changes.•Findings were stable with small samples; uncertainty increases with fewer data.•Speech features detected changes even when ALSFRS-R showed no change.</description><identifier>ISSN: 0010-4825</identifier><identifier>ISSN: 1879-0534</identifier><identifier>EISSN: 1879-0534</identifier><identifier>DOI: 10.1016/j.compbiomed.2024.108949</identifier><identifier>PMID: 39126786</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Adult ; Aged ; Amyotrophic lateral sclerosis ; Amyotrophic Lateral Sclerosis - physiopathology ; Audio data ; Biomarkers ; Biomedical speech and voice signal processing ; Clinical trials ; Continuous bridges ; Disease Progression ; Explainability ; Female ; Functionals ; Human motion ; Humans ; Male ; Middle Aged ; Multimodal digital biomarkers ; Neurodegenerative diseases ; Remote monitoring ; Remote patient monitoring ; Speech ; Speech - physiology ; Speech recognition ; Telemedicine</subject><ispartof>Computers in biology and medicine, 2024-09, Vol.180, p.108949, Article 108949</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1926-371bef379c93385d3ed54bb16eb6a927483e684106ca29836b3ed3859b5129233</cites><orcidid>0000-0001-7810-2769 ; 0000-0003-4305-0334 ; 0000-0002-1023-9061</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.compbiomed.2024.108949$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39126786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neumann, Michael</creatorcontrib><creatorcontrib>Kothare, Hardik</creatorcontrib><creatorcontrib>Ramanarayanan, Vikram</creatorcontrib><title>Multimodal speech biomarkers for remote monitoring of ALS disease progression</title><title>Computers in biology and medicine</title><addtitle>Comput Biol Med</addtitle><description>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that severely impacts affected persons’ speech and motor functions, yet early detection and tracking of disease progression remain challenging. The current gold standard for monitoring ALS progression, the ALS functional rating scale - revised (ALSFRS-R), is based on subjective ratings of symptom severity, and may not capture subtle but clinically meaningful changes due to a lack of granularity. Multimodal speech measures which can be automatically collected from patients in a remote fashion allow us to bridge this gap because they are continuous-valued and therefore, potentially more granular at capturing disease progression. Here we investigate the responsiveness and sensitivity of multimodal speech measures in persons with ALS (pALS) collected via a remote patient monitoring platform in an effort to quantify how long it takes to detect a clinically-meaningful change associated with disease progression. We recorded audio and video from 278 participants and automatically extracted multimodal speech biomarkers (acoustic, orofacial, linguistic) from the data. We find that the timing alignment of pALS speech relative to a canonical elicitation of the same prompt and the number of words used to describe a picture are the most responsive measures at detecting such change in both pALS with bulbar (n = 36) and non-bulbar onset (n = 107). Interestingly, the responsiveness of these measures is stable even at small sample sizes. We further found that certain speech measures are sensitive enough to track bulbar decline even when there is no patient-reported clinical change, i.e. the ALSFRS-R speech score remains unchanged at 3 out of a total possible score of 4. The findings of this study have the potential to facilitate improved, accelerated and cost-effective clinical trials and care.
•Multimodal speech biomarkers can be reliably extracted from remote recordings.•Nine features showed significant longitudinal changes in people with ALS.•Canonical timing alignment quickly detected clinically relevant changes.•Findings were stable with small samples; uncertainty increases with fewer data.•Speech features detected changes even when ALSFRS-R showed no change.</description><subject>Adult</subject><subject>Aged</subject><subject>Amyotrophic lateral sclerosis</subject><subject>Amyotrophic Lateral Sclerosis - physiopathology</subject><subject>Audio data</subject><subject>Biomarkers</subject><subject>Biomedical speech and voice signal processing</subject><subject>Clinical trials</subject><subject>Continuous bridges</subject><subject>Disease Progression</subject><subject>Explainability</subject><subject>Female</subject><subject>Functionals</subject><subject>Human motion</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multimodal digital biomarkers</subject><subject>Neurodegenerative diseases</subject><subject>Remote monitoring</subject><subject>Remote patient monitoring</subject><subject>Speech</subject><subject>Speech - physiology</subject><subject>Speech recognition</subject><subject>Telemedicine</subject><issn>0010-4825</issn><issn>1879-0534</issn><issn>1879-0534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1LwzAUhoMoOqd_QQLeeNOZjzZNLufwCza8UK9Dm57OzLaZSSv4703ZRPDGq0DynPc9eRDClMwooeJ6MzOu3ZbWtVDNGGFpvJYqVQdoQmWuEpLx9BBNCKEkSSXLTtBpCBtCSEo4OUYnXFEmcikmaLUamt62rioaHLYA5g2PsYV_Bx9w7Tz20LoecOs62ztvuzV2NZ4vn3FlAxQB8Na7tYcQrOvO0FFdNAHO9-cUvd7dviwekuXT_eNivkwMVUwkPKcl1DxXRnEus4pDlaVlSQWUolAsTyUHIVNKhCmYklyUkYigKjPKFON8iq52ubH7Y4DQ69YGA01TdOCGoDmJH5Q5zVlEL_-gGzf4Lm43UkJkOZVjoNxRxrsQPNR662208KUp0aNyvdG_yvWoXO-Ux9GLfcFQjm8_gz-OI3CzAyAa-bTgdTAWOgOV9WB6XTn7f8s3k06V4A</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Neumann, Michael</creator><creator>Kothare, Hardik</creator><creator>Ramanarayanan, Vikram</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>JQ2</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7810-2769</orcidid><orcidid>https://orcid.org/0000-0003-4305-0334</orcidid><orcidid>https://orcid.org/0000-0002-1023-9061</orcidid></search><sort><creationdate>202409</creationdate><title>Multimodal speech biomarkers for remote monitoring of ALS disease progression</title><author>Neumann, Michael ; Kothare, Hardik ; Ramanarayanan, Vikram</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1926-371bef379c93385d3ed54bb16eb6a927483e684106ca29836b3ed3859b5129233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Amyotrophic lateral sclerosis</topic><topic>Amyotrophic Lateral Sclerosis - physiopathology</topic><topic>Audio data</topic><topic>Biomarkers</topic><topic>Biomedical speech and voice signal processing</topic><topic>Clinical trials</topic><topic>Continuous bridges</topic><topic>Disease Progression</topic><topic>Explainability</topic><topic>Female</topic><topic>Functionals</topic><topic>Human motion</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multimodal digital biomarkers</topic><topic>Neurodegenerative diseases</topic><topic>Remote monitoring</topic><topic>Remote patient monitoring</topic><topic>Speech</topic><topic>Speech - physiology</topic><topic>Speech recognition</topic><topic>Telemedicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neumann, Michael</creatorcontrib><creatorcontrib>Kothare, Hardik</creatorcontrib><creatorcontrib>Ramanarayanan, Vikram</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Computers in biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neumann, Michael</au><au>Kothare, Hardik</au><au>Ramanarayanan, Vikram</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multimodal speech biomarkers for remote monitoring of ALS disease progression</atitle><jtitle>Computers in biology and medicine</jtitle><addtitle>Comput Biol Med</addtitle><date>2024-09</date><risdate>2024</risdate><volume>180</volume><spage>108949</spage><pages>108949-</pages><artnum>108949</artnum><issn>0010-4825</issn><issn>1879-0534</issn><eissn>1879-0534</eissn><abstract>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that severely impacts affected persons’ speech and motor functions, yet early detection and tracking of disease progression remain challenging. The current gold standard for monitoring ALS progression, the ALS functional rating scale - revised (ALSFRS-R), is based on subjective ratings of symptom severity, and may not capture subtle but clinically meaningful changes due to a lack of granularity. Multimodal speech measures which can be automatically collected from patients in a remote fashion allow us to bridge this gap because they are continuous-valued and therefore, potentially more granular at capturing disease progression. Here we investigate the responsiveness and sensitivity of multimodal speech measures in persons with ALS (pALS) collected via a remote patient monitoring platform in an effort to quantify how long it takes to detect a clinically-meaningful change associated with disease progression. We recorded audio and video from 278 participants and automatically extracted multimodal speech biomarkers (acoustic, orofacial, linguistic) from the data. We find that the timing alignment of pALS speech relative to a canonical elicitation of the same prompt and the number of words used to describe a picture are the most responsive measures at detecting such change in both pALS with bulbar (n = 36) and non-bulbar onset (n = 107). Interestingly, the responsiveness of these measures is stable even at small sample sizes. We further found that certain speech measures are sensitive enough to track bulbar decline even when there is no patient-reported clinical change, i.e. the ALSFRS-R speech score remains unchanged at 3 out of a total possible score of 4. The findings of this study have the potential to facilitate improved, accelerated and cost-effective clinical trials and care.
•Multimodal speech biomarkers can be reliably extracted from remote recordings.•Nine features showed significant longitudinal changes in people with ALS.•Canonical timing alignment quickly detected clinically relevant changes.•Findings were stable with small samples; uncertainty increases with fewer data.•Speech features detected changes even when ALSFRS-R showed no change.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>39126786</pmid><doi>10.1016/j.compbiomed.2024.108949</doi><orcidid>https://orcid.org/0000-0001-7810-2769</orcidid><orcidid>https://orcid.org/0000-0003-4305-0334</orcidid><orcidid>https://orcid.org/0000-0002-1023-9061</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0010-4825 |
ispartof | Computers in biology and medicine, 2024-09, Vol.180, p.108949, Article 108949 |
issn | 0010-4825 1879-0534 1879-0534 |
language | eng |
recordid | cdi_proquest_miscellaneous_3091287172 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Adult Aged Amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis - physiopathology Audio data Biomarkers Biomedical speech and voice signal processing Clinical trials Continuous bridges Disease Progression Explainability Female Functionals Human motion Humans Male Middle Aged Multimodal digital biomarkers Neurodegenerative diseases Remote monitoring Remote patient monitoring Speech Speech - physiology Speech recognition Telemedicine |
title | Multimodal speech biomarkers for remote monitoring of ALS disease progression |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A11%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multimodal%20speech%20biomarkers%20for%20remote%20monitoring%20of%20ALS%20disease%20progression&rft.jtitle=Computers%20in%20biology%20and%20medicine&rft.au=Neumann,%20Michael&rft.date=2024-09&rft.volume=180&rft.spage=108949&rft.pages=108949-&rft.artnum=108949&rft.issn=0010-4825&rft.eissn=1879-0534&rft_id=info:doi/10.1016/j.compbiomed.2024.108949&rft_dat=%3Cproquest_cross%3E3096657183%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3096657183&rft_id=info:pmid/39126786&rft_els_id=S0010482524010345&rfr_iscdi=true |